JP2024507937A - Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体 - Google Patents

Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体 Download PDF

Info

Publication number
JP2024507937A
JP2024507937A JP2023551762A JP2023551762A JP2024507937A JP 2024507937 A JP2024507937 A JP 2024507937A JP 2023551762 A JP2023551762 A JP 2023551762A JP 2023551762 A JP2023551762 A JP 2023551762A JP 2024507937 A JP2024507937 A JP 2024507937A
Authority
JP
Japan
Prior art keywords
seq
set forth
sequence set
antibody
binding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551762A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022180271A5 (https=
JP2024507937A5 (https=
Inventor
コーネリス ルーバーズ，ロベルトゥス
デル ヴリット，ヨハネス ジェレ ヴァン
フルシク，デイヴィッド ルジェ
ウィレム アンリ イダ パーレン，ポール
マタイス ルーベン，ジャーレン
メレーテ ムセ，シャーロット
Original Assignee
ラヴァ・セラピューティクス・エヌ・ヴイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラヴァ・セラピューティクス・エヌ・ヴイ filed Critical ラヴァ・セラピューティクス・エヌ・ヴイ
Publication of JP2024507937A publication Critical patent/JP2024507937A/ja
Publication of JPWO2022180271A5 publication Critical patent/JPWO2022180271A5/ja
Publication of JP2024507937A5 publication Critical patent/JP2024507937A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023551762A 2021-02-26 2022-02-28 Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体 Pending JP2024507937A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP21159698.6 2021-02-26
EP21159698 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US63/166,339 2021-03-26
US202163274709P 2021-11-02 2021-11-02
US63/274,709 2021-11-02
EP21211114.0 2021-11-29
EP21211114 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (3)

Publication Number Publication Date
JP2024507937A true JP2024507937A (ja) 2024-02-21
JPWO2022180271A5 JPWO2022180271A5 (https=) 2025-02-27
JP2024507937A5 JP2024507937A5 (https=) 2025-02-27

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551762A Pending JP2024507937A (ja) 2021-02-26 2022-02-28 Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体

Country Status (9)

Country Link
US (1) US20240141071A1 (https=)
EP (1) EP4298125A1 (https=)
JP (1) JP2024507937A (https=)
KR (1) KR20230169950A (https=)
AU (1) AU2022225091A1 (https=)
BR (1) BR112023017099A2 (https=)
CA (1) CA3209454A1 (https=)
MX (1) MX2023009950A (https=)
WO (1) WO2022180271A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2025012118A2 (en) * 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
WO2020227071A1 (en) * 2019-05-04 2020-11-12 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
SI2838917T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
EP3965818A4 (en) 2019-05-08 2023-05-31 Janssen Biotech, Inc. MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513521A (ja) * 2014-04-10 2017-06-01 シュティヒティング・フェーウーエムセー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
WO2020227071A1 (en) * 2019-05-04 2020-11-12 Inhibrx, Inc. Cd123-binding polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEUKEMIA, vol. 35, JPN6026003404, 2020, pages 2274 - 2284, ISSN: 0005783718 *

Also Published As

Publication number Publication date
KR20230169950A (ko) 2023-12-18
BR112023017099A2 (pt) 2023-11-21
MX2023009950A (es) 2023-11-10
EP4298125A1 (en) 2024-01-03
US20240141071A1 (en) 2024-05-02
WO2022180271A1 (en) 2022-09-01
AU2022225091A1 (en) 2023-09-07
CA3209454A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
TWI830151B (zh) 抗GPRC5DxBCMAxCD3三特異性抗體及其用途
JP7269215B2 (ja) 抗ｃｄ３抗体、抗ｃｄ１２３抗体及びｃｄ３及び／又はｃｄ１２３に特異的に結合する二重特異性抗体
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
US11952421B2 (en) Bispecific antibodies against CD3EPSILON and ROR1
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
KR20220050971A (ko) 신규 항-cd39 항체
CN111971298B (zh) 抗体
CN113874400A (zh) 抗Vβ17/抗CD123双特异性抗体
JP2024501403A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
TW202346337A (zh) Ilt3及cd3結合劑以及其使用方法
US20250230240A1 (en) Variant antibodies that bind gamma-delta t cell receptors
CN119173528A (zh) 针对cd277和肿瘤抗原的双特异性抗体
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
KR20260051069A (ko) 안정화된 cd3 항원 결합제 및 그 사용 방법
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
CN117986371A (zh) 结合CD123和γ-δT细胞受体的抗体
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors
JP2025525291A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体を含む組成物
CN121127496A (zh) 抗Vβ17/抗CD123双特异性抗体
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物
EA051514B1 (ru) Полипептидные конструкции, селективно связывающиеся с cldn6 и cd3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260130